7,625 results
P
patients receiving postpyloric nasoenteric tube placement
I/C
prokinetic drugs, placebo
O
success of postpyloric nasoenteric tube placement
P
Alzheimer's disease, non-steroidal anti-inflammatory drugs
I/C
non-steroidal anti-inflammatory drugs, no intervention
O
Alzheimer's disease
P
horses with osteoarthritis
I/C
hyaluronic acid (HyA), polyacrylamide hydrogel (PHyd), associated or not with other drugs
O
lameness reduction
P
Multiple studies on treatments of interest
I/C
Standard network meta-analysis and indirect comparisons, Multilevel network meta-regression (ML-NMR), Matching-adjusted indirect comparison (MAIC), Simulated treatment comparison (STC), Population adjustment methods using individual patient data
O
Bias elimination, Robust techniques for population adjustment
P
individuals diagnosed with drug use disorders
I/C
preventing and treating drug use disorders, individuals without drug use disorders
O
risk of violence against others
P
people with diabetic macular oedema (DMO)
I/C
anti-vascular endothelial growth factor (anti-VEGF) therapy, other treatments, sham, or no treatment
O
change in best-corrected visual acuity (BCVA) at 24 months, central retinal thickness (CRT) reduction at 24 months, all-cause mortality at longest available follow-up
P
Helicobacter pylori, probiotics, randomized controlled trials
I/C
standard triple therapy, network meta-analysis, Bayesian network meta-analysis, different probiotics, adding probiotics before or after triple therapy, combination of different probiotics
O
eradication rate, side effects, therapeutic effect
P
COVID-19, Sars-CoV-2
I/C
Psychotropic drugs, Antidepressants, Mood stabilizers, Antipsychotics, No intervention, Other psychotropic drugs
O
Severe COVID-19, Mortality
P
breast cancer patients
I/C
nonpharmacologic interventions, no studies have compared their effectiveness
O
chemotherapy-related cognitive impairment (CRCI)